Taylor Ben R
Chief Financial Officer
Taylor Ben R has filed 12 SEC Form 4 filings (16 transaction rows) across 1 company, with disclosures dating back to 2025. 12 of those filings fall inside the rolling window. Most recent filing: Aug 18, 2026.
On the most recent filing, Taylor Ben R is listed as Chief Financial Officer at RECURSION PHARMACEUTICALS, INC. Inside the rolling window, Taylor Ben R reported no open-market purchases and 3 open-market sales totaling $158K in RXRX. The largest disclosed transaction in the window is a sale of 21,383 RXRX shares on Dec 29, 2025, worth $89K.
Companies traded
Other insiders at RXRX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$158K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Taylor Ben R made?
Taylor Ben R has filed 12 SEC Form 4 filings (16 transaction rows) across 1 company since 2025.
Which companies does Taylor Ben R trade?
Taylor Ben R has filed SEC Form 4 disclosures for 1 company, including RXRX.
When was Taylor Ben R's most recent SEC Form 4 filing?
Taylor Ben R's most recent SEC Form 4 filing on Tracefour is dated Aug 18, 2026.
What is Taylor Ben R's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Taylor Ben R is listed as Chief Financial Officer.
What is Taylor Ben R's total buy and sell value in the current window?
Inside the rolling retention window, Taylor Ben R bought $0 and sold $158K based on SEC Form 4 filings.
What was Taylor Ben R's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 21,383 RXRX shares on 2025-12-29, worth $89K, per SEC Form 4 filings.